Who can prescribe Strattera? NP vs MD in Pennsylvania

If you’ve been wondering whether you can get ADHD treatment online—specifically non-stimulant medications like Strattera—the short answer is yes. But as with most healthcare questions, the full picture involves understanding federal regulations, state-specific rules, and what quality telehealth care actually looks like.

Let’s walk through everything you need to know about accessing non-stimulant ADHD medication via telehealth in 2025.

Understanding ADHD Non-Stimulant Medications

Before diving into telehealth regulations, it’s important to understand what we’re talking about when we say ‘non-stimulant ADHD medication.’

Strattera (atomoxetine) is the most commonly prescribed non-stimulant for ADHD. Unlike Adderall or Ritalin, Strattera is not a controlled substance—meaning it doesn’t carry the same risk of abuse or dependency. The FDA has confirmed that atomoxetine is not habit-forming, which fundamentally changes how it can be prescribed and monitored.

Other non-stimulant options include:

• Intuniv (guanfacine)
• Kapvay (clonidine)
• Qelbree (viloxazine)

These medications work differently than stimulants. Rather than providing immediate symptom relief, non-stimulants typically take 4-6 weeks to reach full effectiveness. They work by gradually adjusting neurotransmitter levels in the brain, particularly norepinephrine, which plays a key role in attention and impulse control.

Free consultations available with select providers only.

Get a free consultation

And find an affordable, caring specialist.

Find a provider

Free consultations available with select providers only.

The Big Question: Is Telehealth Prescribing Legal for ADHD Meds?

Here’s where things get interesting—and where many people get confused.

For Non-Stimulant Medications (Like Strattera)

Yes, absolutely legal nationwide. Because Strattera and similar non-stimulants aren’t controlled substances, they’re not subject to the Drug Enforcement Administration’s special prescribing rules. There’s no federal requirement for an in-person exam before prescribing them via telehealth.

A licensed healthcare provider can evaluate you through a video visit, confirm an ADHD diagnosis using established diagnostic criteria, and electronically prescribe Strattera—all completely legally and safely.

For Stimulant Medications (Like Adderall or Vyvanse)

This is more complicated. Stimulants are Schedule II controlled substances, which normally require an in-person medical evaluation under the Ryan Haight Act of 2008. However, during the COVID-19 pandemic, the DEA temporarily waived this requirement.

Current status as of December 2025: The DEA has extended telehealth prescribing flexibility for controlled substances through December 31, 2025. This means qualified providers can currently prescribe stimulant ADHD medications via telehealth without a prior in-person visit. A fourth extension for 2026 is anticipated and currently under review, though nothing has been finalized yet.

State-by-State Variations: What You Need to Know

While federal law sets the baseline, individual states add their own layers of regulation. Here’s what matters most in key states:

California

California embraces telehealth for ADHD treatment with minimal restrictions. There’s no state-mandated in-person exam requirement for non-controlled medications. Nurse practitioners in California can practice independently after meeting experience requirements, and they can prescribe both stimulant and non-stimulant ADHD medications.

Bottom line: California residents have excellent access to telehealth ADHD care, including both stimulant and non-stimulant options.

New York

New York implemented stricter rules in 2025. The state now requires an initial in-person evaluation before prescribing any controlled substance via telehealth—but this only applies to stimulants, not to Strattera or other non-controlled medications.

Bottom line: NY residents can access Strattera via telehealth without an in-person visit, but stimulant medications require an initial face-to-face evaluation.

Florida

Florida has an interesting carve-out: the state generally prohibits telehealth prescribing of Schedule II drugs, but makes an explicit exception for psychiatric conditions—and ADHD qualifies. For non-stimulants like Strattera, there are no special restrictions beyond standard telehealth requirements.

Bottom line: Both stimulant and non-stimulant ADHD medications can be prescribed via telehealth in Florida, as long as the provider is treating a diagnosed psychiatric condition.

Texas

Texas is telehealth-friendly for mental health services, with no blanket in-person requirement for ADHD treatment. However, there’s an important limitation: nurse practitioners and physician assistants in Texas cannot prescribe Schedule II medications (like Adderall) in regular outpatient settings—only in hospitals or hospice care. Physicians face no such restriction.

For Strattera and other non-stimulants, both MDs and NPs can prescribe via telehealth without issue.

Bottom line: If you’re working with a physician in Texas, you have full access to telehealth ADHD treatment. If you’re seeing an NP or PA, you may be limited to non-stimulant options.

Alabama

Alabama has some of the strictest telehealth rules in the nation. The state requires an in-person visit within 12 months if you’re receiving ongoing telehealth treatment—though mental health services are exempt from this rule, which often includes ADHD care.

Bottom line: Alabama’s rules are complex, but for psychiatric telehealth (including ADHD), the strict in-person requirements generally don’t apply.

New Hampshire

In a significant 2025 update, New Hampshire removed its prior in-person requirement. Now, providers must conduct a follow-up evaluation at least annually for patients on controlled medications, but this evaluation can be done via telehealth.

Bottom line: New Hampshire significantly expanded telehealth access in 2025, making it easier than ever to start ADHD treatment remotely.

Who Can Prescribe ADHD Medications Via Telehealth?

Not all healthcare providers have the same prescribing authority. Here’s what you need to know:

Physicians (MD/DO)

Licensed physicians can prescribe both stimulant and non-stimulant ADHD medications via telehealth in all 50 states, assuming they’re licensed in your state and follow applicable DEA and state regulations. This is the most straightforward path for accessing ADHD medication through telehealth.

Nurse Practitioners (NP)

NP prescribing authority varies significantly by state:

Full Independent Practice States (including New York, Illinois, New Hampshire): NPs can prescribe Schedule II-V controlled substances independently after completing required experience hours and obtaining DEA registration.

Collaborative Practice States (including Florida, Pennsylvania): NPs must have a physician collaboration agreement but can still prescribe ADHD medications within that framework.

Restricted States (including Georgia): Some states prohibit NPs from prescribing Schedule II medications entirely. In these states, NPs can prescribe non-stimulants like Strattera but would need to refer to a physician for stimulant medications.

Physician Assistants (PA)

PAs typically operate under physician supervision or collaboration agreements. Their controlled substance prescribing authority varies by state, with restrictions similar to those faced by NPs.

For non-stimulant medications like Strattera: All NPs and PAs in every state can prescribe these under their standard scope of practice (with required supervisory agreements where applicable).

What Does a Quality Telehealth ADHD Evaluation Look Like?

Here’s something crucial to understand: legitimate telehealth ADHD care isn’t a quick online quiz followed by an automatic prescription. Reputable providers follow the same diagnostic standards as in-person care.

Comprehensive Initial Assessment

A thorough telehealth ADHD evaluation typically includes:

Detailed symptom history: Your provider will ask about attention difficulties, hyperactivity, impulsivity, and how these symptoms affect multiple areas of your life—work, relationships, daily tasks.

Childhood onset verification: ADHD symptoms must have been present before age 12. Providers may ask about school records, report cards, or input from family members who knew you as a child.

DSM-5 diagnostic criteria: Your clinician will systematically assess whether you meet the established diagnostic criteria, which require a specific number and pattern of symptoms.

Differential diagnosis: Good providers rule out other conditions that can mimic ADHD, such as anxiety, depression, sleep disorders, or thyroid problems.

Medical history review: They’ll screen for conditions that might contraindicate certain medications—heart problems, glaucoma, severe anxiety, or substance use history.

Risk assessment: Clinicians evaluate factors like history of substance abuse, current mental health stability, and potential for medication misuse.

This evaluation typically takes 45-60 minutes for an initial appointment. If a provider offers to prescribe ADHD medication after a 5-minute chat, that’s a major red flag.

Required Documentation

Expect to provide:

• Photo ID verification
• Insurance information (if applicable)
• Previous medical records (if available)
• Completed screening questionnaires (many platforms send these before your appointment)
• Pharmacy information

The Prescription Process for Strattera

If your provider determines Strattera is appropriate, here’s what happens:

No DEA restrictions: Because Strattera isn’t controlled, there are no federal limits on supply duration. Providers often prescribe 90-day supplies with multiple refills—up to a year in many cases.

Electronic prescribing: Your prescription is sent electronically to your chosen pharmacy. Most major chains fill telehealth prescriptions without issue.

Starting low, going slow: Strattera typically starts at a low dose (often 40mg daily for adults) and gradually increases based on response and tolerability. Your provider will schedule follow-ups to adjust dosing.

No monthly appointments required: Unlike stimulant medications (which often require monthly check-ins due to their controlled status), Strattera allows for less frequent monitoring once you’re stable—often every 3-6 months.

The Klarity Health Advantage for ADHD Care

When you’re considering telehealth for ADHD treatment, choosing the right platform matters. Klarity Health offers several advantages that set it apart:

Provider availability: Klarity maintains a network of board-certified psychiatrists, psychiatric nurse practitioners, and other qualified mental health professionals across multiple states. You’re not waiting weeks for an appointment—many patients can schedule within days.

Transparent pricing: Whether you’re using insurance or paying out of pocket, Klarity provides upfront pricing information. No surprise bills or hidden fees. Cash-pay options are available for those without insurance or with high-deductible plans, making care accessible regardless of your coverage situation.

Flexible payment options: Klarity accepts both insurance and self-pay, giving you control over how you access care. This flexibility is especially valuable for ADHD treatment, where insurance coverage for telehealth can vary significantly.

Comprehensive approach: Klarity providers don’t just prescribe medication—they consider the whole picture of ADHD management, including therapy referrals, lifestyle modifications, and ongoing support.

Safety Considerations and Red Flags

The ADHD telehealth landscape has matured significantly since the pandemic began, but it’s important to recognize quality care.

Warning Signs of Problematic Telehealth Services

Avoid services that:

• Guarantee prescriptions before evaluation
• Don’t require a video visit (phone-only for initial assessment)
• Skip detailed symptom history
• Never check prescription monitoring programs
• Offer to prescribe any medication you request
• Pressure you toward stimulants over non-stimulants without clinical justification

What Legitimate Providers Do

Quality telehealth services:

• Conduct thorough diagnostic interviews
• Use standardized rating scales and questionnaires
• Check your state’s prescription monitoring program (even for non-controlled meds, as a best practice)
• Discuss both medication and non-medication treatments
• Schedule regular follow-ups to monitor effectiveness and side effects
• Maintain clear communication channels for questions or concerns
• Coordinate with your other healthcare providers when appropriate

Common Patient Questions About Strattera and Telehealth

‘Will my pharmacy fill a telehealth prescription?’

Almost always, yes. Electronic prescriptions are standard practice now, and pharmacies don’t distinguish between telehealth and in-person prescriptions. For Strattera specifically, there’s typically no additional scrutiny since it’s not a controlled substance.

‘How long until Strattera works?’

Unlike stimulants that work within hours, Strattera requires patience. Most people notice initial improvements within 2-3 weeks, with full benefits emerging at 4-6 weeks. Your provider will likely schedule a follow-up around week 4 to assess response and adjust dosing if needed.

‘What if Strattera doesn’t work for me?’

Telehealth providers can adjust treatment plans just like in-person doctors. Options include:

• Adjusting the Strattera dose
• Trying a different non-stimulant
• Considering stimulant medication (following all applicable regulations)
• Referring to in-person specialists if needed
• Exploring combination approaches with therapy

‘Can I switch from stimulants to Strattera via telehealth?’

Yes, this is actually a common scenario. Many people try stimulants first but experience problematic side effects (anxiety, sleep issues, appetite suppression) or prefer to avoid controlled substances. Your telehealth provider can guide this transition, though you should never stop stimulants abruptly without medical guidance.

‘What about drug testing?’

Some telehealth providers require periodic drug screening for patients on stimulant medications, but this is less common for non-stimulants. If your provider suggests testing, it’s typically to ensure medication compliance and detect any concerning substance use—it’s a safety measure, not a judgment.

Cost Considerations

One advantage of Strattera over stimulants is often cost-effectiveness:

Generic availability: Atomoxetine (generic Strattera) is widely available and typically costs $30-100 per month without insurance, compared to $200-400 for brand-name stimulants.

Longer prescriptions: Because it’s not controlled, you can often get 90-day supplies, reducing pharmacy trips and sometimes qualifying for bulk pricing discounts.

Insurance coverage: Most insurance plans cover Strattera as a preferred medication, often with lower copays than stimulants.

Telehealth visit costs: Initial ADHD evaluations via telehealth typically range from $150-300 out-of-pocket, with follow-ups around $75-150. Klarity Health’s transparent pricing helps you know exactly what to expect, and insurance coverage can significantly reduce these costs.

Looking Ahead: What Changes Are Coming?

The telehealth landscape continues to evolve. Here’s what to watch:

DEA regulations: The current telehealth flexibility for controlled substances expires December 31, 2025. While an extension is anticipated, it hasn’t been finalized. This primarily affects stimulant prescribing—non-stimulants like Strattera will remain accessible via telehealth regardless.

State legislation: More states are adopting permanent telehealth statutes, generally expanding (not restricting) access. However, stay informed about your state’s specific rules.

Practice standards: Professional organizations are developing clearer guidelines for telehealth ADHD care, which should improve consistency and quality across providers.

Technology advances: Expect improvements in remote monitoring, digital phenotyping, and integration with wearable devices that could enhance telehealth ADHD management.

Practical Steps to Get Started

Ready to explore telehealth for ADHD treatment? Here’s your action plan:

1. Research your options: Look for platforms with licensed providers in your state, clear policies, and positive patient reviews. Klarity Health checks all these boxes and offers both insurance and cash-pay options for maximum flexibility.

2. Gather your information: Prepare your medical history, current medications, and any previous ADHD evaluations or documentation. The more information you provide, the better your provider can help.

3. Schedule your evaluation: Book an initial assessment. Be honest and thorough during this appointment—your provider needs accurate information to make safe, effective treatment decisions.

4. Set realistic expectations: Remember that ADHD treatment is a process, not a one-time fix. Non-stimulants require time to work, and finding the right medication and dose might take a few adjustments.

5. Plan for follow-up: Mark your calendar for scheduled follow-ups. Consistent communication with your provider is key to successful ADHD management.

6. Consider comprehensive treatment: Medication is just one tool. Ask your provider about therapy, coaching, organizational strategies, and lifestyle modifications that complement medication treatment.

The Bottom Line

Yes, you can absolutely get non-stimulant ADHD medication like Strattera through telehealth—safely, legally, and effectively. The combination of federal flexibility and evolving state policies has made quality ADHD care more accessible than ever before.

The key is choosing a reputable provider who follows proper diagnostic protocols, considers your individual needs, and provides ongoing support. Platforms like Klarity Health make this easier by connecting you with qualified providers, offering transparent pricing, and accepting both insurance and cash payment—removing common barriers to getting the care you need.

If you’ve been struggling with ADHD symptoms and wondering whether telehealth treatment is right for you, there’s never been a better time to explore your options. The convenience of telehealth doesn’t mean compromising on quality care—it means accessing the same rigorous diagnostic standards and treatment expertise from the comfort of your own home.

Ready to take the next step? Consider scheduling an evaluation with a qualified telehealth provider to discuss whether non-stimulant ADHD medication might be right for you. With proper diagnosis and treatment, you can develop effective strategies to manage ADHD symptoms and improve your daily functioning.

References

1. FierceHealthcare. (2024, November). ‘DEA Finalizes One-Year Extension of Controlled Substance Prescribing Via Telehealth.’ Retrieved from www.fiercehealthcare.com

2. McDermott Will & Emery. (2025). ‘DEA Signals Extension of Telemedicine Flexibilities for Controlled Substance Prescribing for 2026.’ Retrieved from www.mwe.com

3. Sheppard Mullin Healthcare Law Blog / National Law Review. (2025, August 15). ‘Telehealth and In-Person Visits: Tracking Federal and State Updates to Pandemic-Era Telehealth Exceptions.’ Retrieved from www.sheppardhealthlaw.com

4. RxAgent. (2025, October). ‘Telehealth Compliance Trap: Why Your ‘Legal’ ADHD Prescriptions Could Land You in Federal Court.’ Retrieved from www.rxagent.co

5. Medical News Today. (2025, January 14). ‘Is Strattera a Controlled Substance?’ Retrieved from www.medicalnewstoday.com

Source:

• https://www.fiercehealthcare.com/regulatory/dea-finalizes-one-year-extension-controlled-substance-prescribing-telehealth-punts-final#:~:text=The%20Drug%20Enforcement%20Administration%20,Federal%20Register%20on%20Friday%20night
• https://www.mwe.com/insights/dea-signals-extension-of-telemedicine-flexibilities-for-controlled-substance-prescribing-for-2026/#:~:text=visit,examination%20through%20December%2031%2C%202025
• https://www.mwe.com/insights/dea-signals-extension-of-telemedicine-flexibilities-for-controlled-substance-prescribing-for-2026/#:~:text=A%20new%20rule%20posted%20on,date%20of%20December%2031%2C%202025
• https://www.fiercehealthcare.com/regulatory/dea-finalizes-one-year-extension-controlled-substance-prescribing-telehealth-punts-final#:~:text=The%20%E2%80%9CThird%20Temporary%20Extension%20of,14
• https://www.medicalnewstoday.com/articles/drugs-is-strattera-a-controlled-substance#:~:text=Strattera%20,such%20as%20mental%20health%20issues
• https://www.sheppardhealthlaw.com/2025/08/articles/telehealth/telehealth-and-in-person-visits-tracking-federal-and-state-updates-to-pandemic-era-telehealth-exceptions/#:~:text=In%20late%202024%2C%20the%20U,prescribing
• https://www.rxagent.co/blog/telehealth-compliance-trap#:~:text=The%20,False%20Hope
• https://www.techtarget.com/virtualhealthcare/news/366616019/Telehealth-prescribing-flexibility-extended-through-2025#:~:text=Image%20filo%2FDigitalVision%20Vectors%20via%20G,The
• https://natlawreview.com/article/telehealth-and-person-visits-tracking-federal-and-state-updates-pandemic-era?amp=#:~:text=Extend%20natlawreview,before%20issuing%20a%20dangerous%20drug
• https://www.rxagent.co/blog/telehealth-compliance-trap#:~:text=,specifically%20for%20chronic%20pain%20treatment